Stupp, Roger

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 21,807

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 7,405

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial

Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA

Glioma Diagnosis and TreatmentElectromagnetic Fields and Biological Effects

Cited by 2,644

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA

Glioma Diagnosis and TreatmentMathematical Biology Tumor Growth

Cited by 1,259

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 1,063

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 1,052

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer

Glioma Diagnosis and TreatmentElectromagnetic Fields and Biological Effects

Cited by 862

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., Taphoorn, M. J. B., Hassel, M. B., et al. (2016) · The Lancet Oncology

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 495

Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer

Posch, F., Silina, K., Leibl, S., Mündlein, A., Moch, H., Siebenhüner, A., Samaras, P., Riedl, J., Stotz, M., Szkandera, J., et al. (2018) · OncoImmunology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 380

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology

Glioma Diagnosis and TreatmentCancer survivorship and care

Cited by 372

Tumor treating fields: A novel treatment modality and its use in brain tumors

Hottinger, A. F., Pacheco, P., & Stupp, R. (2016) · Neuro-Oncology

Glioma Diagnosis and TreatmentElectromagnetic Fields and Biological Effects

Cited by 177

Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients

Maringwa, J., Quinten, C., King, M., Ringash, J., Osoba, D., Coens, C., Martinelli, F., Reeve, B. B., Gotay, C., Greimel, E., et al. (2011) · Annals of Oncology

Cancer survivorship and careHealth Systems, Economic Evaluations, Quality of Life

Cited by 161

Biological activity of tumor-treating fields in preclinical glioma models

Silginer, M., Weller, M., Stupp, R., & Roth, P. (2017) · Cell Death & Disease

Glioma Diagnosis and TreatmentElectromagnetic Fields and Biological Effects

Cited by 111